Evangelia Matenoglou

This study identifies ELV-3111, a Type 1 RAF inhibitor that selectively suppresses MAPK and tumor growth by exploiting distinct binding kinetics, showing efficacy in RAS-mutant and BRAF-mutant models.

The paper shows RAF/MEK glues enable full-dose combination with pan-RAF inhibitors, enhancing tumor-selective MAPK inhibition and tumor regression in RAS-mutant models.

This study uses molecular dynamics simulations to uncover the mechanism of dimer selectivity and binding cooperativity of BRAF inhibitors, revealing structural changes and hydrogen bonding that influence inhibitor binding preferences.